Emerging Primary Amoxicillin Resistance in Helicobacter pylori in Vietnam: Evidence of Erosion of a Long-Standing Beta-Lactam Backbone [0.03%]
越南胃幽门螺旋杆菌对阿莫西林的耐药性增强：长期存在的青霉素类药物支干疗效下降的证据
Duc Trong Quach,Anh Tuan Nguyen,Nhu Thi Hanh Vu et al.
Duc Trong Quach et al.
Exploration of a Potential Amoxicillin MIC Threshold in Bismuth Quadruple Therapy for H. pylori Infection in Southeastern China [0.03%]
铋剂四联疗法治疗中国东南部地区幽门螺杆菌感染潜在的阿莫西林MIC阈值探索研究
Ding Lu,Zhen-Wei Yang,Yun-Fan Dong et al.
Ding Lu et al.
Objective: The European Committee on Antimicrobial Susceptibility Testing (EUCAST) defines the amoxicillin resistance breakpoint at a minimum inhibitory concentration (MIC) of 0.125 μg/mL. This breakpoint is widely appli...
Individuals and Family-Screen-to-Treat-Based Helicobacter pylori Eradication Strategy for Gastric Cancer Prevention: A Latin American Perspective [0.03%]
基于个体和家庭的“检测并治疗”根除幽门螺旋杆菌策略在胃癌预防中的应用——拉丁美洲视角
José Darío Portillo-Miño,Javier Uribe,Gonzalo Latorre et al.
José Darío Portillo-Miño et al.
Gastric cancer (GC) is a public health concern due to estimates indicating it ranks among the most prevalent cancers and leading causes of cancer-related deaths globally. In Latin America, a region significantly impacted by high mortality a...
Hope Hp-GC Project-Program Implementation for Primary and Secondary Prevention of Gastric Cancer in Latin America [0.03%]
拉丁美洲胃癌一级和二级预防的希望Hp-GC项目-计划实施
Javier Uribe,José Darío Portillo-Miño,Gonzalo Latorre et al.
Javier Uribe et al.
Introduction: Gastric cancer (GC) is the fifth leading cause of cancer-related mortality globally; its main burden is concentrated in East Asia and some areas of Europe and Latin America. This study aims to develop an org...
Marcis Leja,Danute Ražuka-Ebela,Bojan Tepes et al.
Marcis Leja et al.
Background: Gastric cancer continues to impose a substantial health burden in Europe. The European Council Recommendations have called for consideration of implementing measures aimed at reducing gastric cancer-related mo...
Susceptibility-Guided Versus Empirical First-Line Therapy of Helicobacter pylori Infection in Adults: A Systematic Review and Meta-Analysis [0.03%]
基于药物敏感性指导与经验性根除Hp感染的随机对照研究的 meta 分析
Manuel Coelho Rocha,Tiago Gaspar,Carlos Bernardes et al.
Manuel Coelho Rocha et al.
Background: Antimicrobial resistance undermines empirical first-line regimens for Helicobacter pylori. We compared susceptibility-guided therapy (SGT) versus empirical therapy in adults receiving first-line treatment, foc...
Advancing Gastric Cancer Prevention in Korea: Current Strategies and Future Directions [0.03%]
韩国胃癌防治的现状与展望
Jin Young Park,Il Ju Choi
Jin Young Park
Background: Korea has historically borne a high burden of gastric cancer, although substantial epidemiological transitions have occurred over recent decades. Gastric cancer was the most common cancer until 2018, but decli...
Journey Towards Piloting Helicobacter pylori Screen-and-Treat to Address Health Inequities in Aotearoa New Zealand [0.03%]
幽门螺杆菌筛查与治疗计划在新西兰的试点工作及其对卫生公平性的影响探究
Andrea Teng,James Stanley,Melissa McLeod
Andrea Teng
Background: Māori and Pacific peoples in Aotearoa New Zealand (Aotearoa) face the greatest barriers to healthcare access, poorest health outcomes, and disproportionate levels of deprivation. ...
David Y Graham
David Y Graham
Real-World Effectiveness and Safety of Saccharomyces boulardii CNCM I-745 as Adjunct Therapy for Helicobacter pylori Eradication: Data From the European Registry on H. pylori Management (Hp-EuReg) [0.03%]
秘鲁自然菌株CNCM I-745作为幽门螺杆菌根除辅助治疗的效果和安全性：来自欧洲幽门螺杆菌管理登记处（Hp-EuReg）的数据
Olga P Nyssen,Laimas Jonaitis,Ángeles Pérez-Aísa et al.
Olga P Nyssen et al.
Background: Saccharomyces boulardii CNCM I-745 (Sb) is one of the most widely used probiotics in clinical practice. The aim of this study was to assess the impact of adding Sb to Helicobacter pylori eradication therapy on...